Clinical Study Program Articles & Analysis: Older
19 news found
The Company also initiated pre-clinical and clinical studies on KK-LC-1 TCR-T with Rutgers University in 2021. ...
AOBiome Therapeutics, Inc. ("AOBiome"), a leading clinical-stage microbiome company focusing on the research and development of a novel class of drugs for inflammatory conditions, central nervous system disorders, and other systemic diseases, today announced that Dr. ...
Botanix (ASX:BOT) has today published its Quarterly Activities Report and 4C Quarterly Cash Flow Report, for the period ended 31 March 2022 Key highlights from this period include: Strategic appointments to Botanix’s executive leadership team,including Dr Patty Walker as Chief Medical Officer and Mr Howie McKibbon as Chief Commercial Officer Danny Sharp also joins as Non-Executive ...
The clinical trial has been authorized by Health Canada, who also recently approved an amendment to the research protocol to increase the dosage of the study drug up to 100 mg of CBD to be assessed in the study. ...
"Importantly, these Phase 2 findings enabled us to advance REL-1017 into the multiple clinical studies RELIANCE Phase 3 program for REL-1017 in MDD." About REL-1017 REL-1017, a new chemical entity (NCE) and novel NMDA receptor (NMDAR) channel blocker that preferentially targets hyperactive channels while maintaining physiological glutamatergic ...
We look forward to providing updates on these clinical outcomes throughout 2022.” Third Quarter 2021 and Subsequent Company Progress Adoptive Cell Therapy Programs ACTengine® IMA203 – On November 13, Dr. ...
Patients with KK-LC-1 positive tumors may be eligible inclusion in clinical trials of a KK-LC-1 targeted T-Cell therapy. Under the terms of the agreement, Atlas Antibodies AB will provide all manufacturing and product supply for KK-LC-1 mAb for the companion diagnostic for clinical development. ...
Sherman Oaks, CA – March 17, 2021 – T-Cure Bioscience, Inc., a privately held company focused on developing T cell receptor (TCR) therapy products for the treatment of solid tumors, today announced that the Company has entered into a clinical research agreement with Rutgers, The State University of New Jersey, to fund a Phase I clinical ...
By leveraging CARD, Computer Accelerated Rational Discovery, a proprietary enabling technology platform, the team has successfully advanced numerous discovery programs in a dramatically accelerated fashion, including from ideas to a clinical start in two years. ...
Moreover, the extensive experience of our management team with the research and clinical development of T cell immunotherapies will be extremely beneficial as we look to initiate clinical trials for ...
The drug received conditional approval in China for the treatment of HER2-positive, advanced or metastatic breast cancer in chemotherapy-treated patients in 2018 based on positive phase 2 clinical trial results and full approval in 2020 based on two successful phase 3 studies. HTI's global clinical trial program for pyrotinib is ...
Anergis SA, a company developing Contiguous Overlapping Peptides (COPs) for ultra-fast allergy immunotherapy, and Virometix AG, a company developing a new generation of vaccines and immunotherapeutic drugs, announced today that they have entered into a research collaboration. The study will be conducted at the Helmholtz Centre for Infection Research (HZI, Braunschweig, Germany) ...
Leon, MD, professor of medicine and Director of the Center for Interventional Vascular Therapy at Columbia University Irving Medical Center and NewYorkPresbyterian, and chairman of the CorCinch-HF study. “The CorCinch clinical programs are developing a new class of therapy and the clinical trials have embraced a strong ...
We are pleased to share the news that Fusion Genomics has received a $1 million award to conduct a study evaluating our comprehensive, novel ONETest PathoGenome assay for the detection of pathogens associated with respiratory tract infections (RTIs). ...
More information about the study is available on ClinicalTrials.gov. The company’s pivotal trial for rotator cuff tendinopathy represents its clinical lead program and builds on positive outcomes of a previous feasibility study reported in December 2018, which found InGeneron’s therapy for rotator cuff tears to be ...
“We are pleased with the progress of our lead AOB programs, including multiple clinical trials focused specifically on inflammatory skin conditions, and we anticipate reporting additional clinical findings from one or more of these studies in ...
CQDM is supporting this project through its SynergiQC program, focusing on industrial research through public and private funding, made possible by a financial contribution from the Ministry of Economy, Science and Innovation (MESI) of the Government of Quebec. ...
He received a B.S. in artificial intelligence and a Ph.D. in bioinformatics from Peking University. "The early successes of our clinical programs have set course for our rapid expansion," stated James Heywood, AOBiome Founder and Board Member. "Pairing Jun's vision with Todd's tactical expertise, AOBiome will continue to seize this moment and significantly ...
Biopticon Corporation Announces the release of the new version of their innovative TumorManagerTM Program for managing pre-clinical oncology study data Innovative instrument and software create revolutionary system to improve data, work-flow and results from in vivo cancer models Princeton, NJ Biopticon today released the latest version of ...